Myomo, Inc.

AMEX:MYO

Medical - Devices

Healthcare
$1.25 -8.80%

-$0.13 today

Market cap
$50.12M
Beta
1.46
P/E (TTM)
-3.6
EPS (TTM)
-$0.36
52W Low $0.61High $2.68

Volume 0.21M

Average 0.62M

MYO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Myomo, Inc.AMEX: MYO

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development dips below year-ago levels

Q1 FY2026 research & development of $1.62M fell 9.3% year over year, behind the +20.9% change in trailing-twelve-month research & development. Sequentially, it fell 0.1% from the prior quarter. Over 3 fiscal years it compounded at +40.9% a year.

Context

  • Research & development amounted to 17.0% of revenue in FY2025, up 2.3 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -9.3% toward the trailing-twelve-month pace of +20.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.62M-0.1% QoQ
Last fiscal yearDec 2025
$6.94M+45.5% YoY
LTMMar 2026
$6.78M+20.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-9.3%——
1 year+45.5%——
3-year CAGR+40.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
6.94M USD
Year-over-year change
+45.5%
4-year CAGR
+28.4%

Research & Development vs competitors

How MYO compares with its peers on the latest reported figures

  • MYO's LTM Mar 2026 research & development of $6.78M is the highest of the 4 companies compared; the peer median is $1.06M.
  • Its year-over-year change of +20.9% is the highest of 4, against a peer median of -17.7%.
  • Research & development amounts to 16.4% of revenue for MYO, versus a peer median of 8.1%.
MYO Competitors Peer median
Research & Development for MYO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MYOMyomo, Inc.LTM Mar 2026$6.78M +20.9%+40.9%16.4%
ECORelectroCore, Inc.LTM Mar 2026$2.83M +8.8%-20.9%8.1%
POCIPrecision Optics Corporation, Inc.LTM Mar 2026$1.06M -17.7%+20.2%3.7%
HYPDHyperion DeFi, Inc.LTM Jun 2026$908.07K -86.6%-47.7%64.8%
Peer median (excluding MYO) $1.06M-17.7%-20.9%8.1%

Competitors are the stored peer set for MYO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue13.86M15.56M19.24M32.55M40.93M
Cost of Revenue3.54M5.3M6.06M9.37M14.04M
Gross Profit10.31M10.25M13.18M23.19M26.89M
Gross Margin74.4%65.9%68.5%71.2%65.7%
Research & Development2.56M2.48M2.64M4.77M6.94M
Selling, General & Admin18.02M18.44M18.78M24.62M34.35M
Operating Expenses20.58M20.93M21.41M29.39M41.29M
Depreciation & Amortization335.96K542.63K517.68K776.97K1.76M
EBITDA(9.95M)(10.11M)(7.47M)(5.04M)(12.38M)
EBITDA Margin-71.8%-65.0%-38.8%-15.5%-30.2%
Operating Income(10.27M)(10.67M)(8.23M)(6.21M)(14.4M)
Operating Margin-74.1%-68.6%-42.8%-19.1%-35.2%
Interest Income1.61K88.73K410.27K388.59K476.97K
Interest Expense0000927.8K
Other Income / Expenses(15.34K)21.12K239.99K388.59K(667.51K)
Income Before Tax(10.28M)(10.65M)(7.99M)(5.82M)(15.07M)
Pre-Tax Margin-74.2%-68.5%-41.5%-17.9%-36.8%
Income Tax Expense88.93K69.94K156K365.62K504.53K
Net Income(10.37M)(10.72M)(8.15M)(6.18M)(15.57M)
Net Margin-74.9%-68.9%-42.3%-19.0%-38.1%
EPS (Basic)(1.78)(1.52)(0.28)(0.16)(0.37)
EPS (Diluted)(1.78)(1.52)(0.28)(0.16)(0.37)
Weighted Avg Shares5.83M7.05M29.1M37.76M41.86M
Weighted Avg Shares (Diluted)5.83M7.05M29.5M37.76M41.86M

Myomo, Inc.

AMEX:MYO

Intrinsic Alpha fair value

Locked

Current Price

$1.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.